Asunercept (APG101) is a Selective CD95L Inhibitor for Glioblastoma Research
Glioblastoma is the most frequent and aggressive form of brain tumour. Significantly, the highly invasive growth of these tumors often prevents complete surgical resection. Consequently, patients progress shortly after surgery. In fact, clinical evidence confirms CD95L as a promising novel target for the treatment of recurrent glioblastoma and potentially...
Efineptakin alfa (NT-17) is a Long-Acting Recombinant Human IL-7 for Glioblastoma Research
In this article, we will introduce a long-acting recombinant human IL-7, Efineptakin alfa. Efineptakin alfa is a potent T-cell amplifier, with a homodimeric IL-7 fused to the hybridizing IgD/IgG4 immunoglobulin domain. Efineptakin alfa supports the proliferation and survival of CD4+ and CD8+ cells in both humans and mice. Patients...
RIPGBM is a Selective Inducer of Apoptosis in Glioblastoma Multiforme Cancer Stem Cells
Glioblastoma multiforme is the most prevalent and aggressive form of primary brain cancer. Glioblastoma multiforme is the most hostile type of brain cancer. Its aggressiveness is due to increased invasion, migration, proliferation, angiogenesis, and a decreased apoptosis. Crucially, a sub-population of multi-potent cells term glioblastoma multiforme cancer stem cells...
JR-AB2-011, a Potential Inhibitor of mTORC2 Activity in Glioblastoma Multiforme (GBM)
Glioblastoma multiforme (GBM) are highly malignant and invasive tumors. It not only can prevent total surgical resection, but also render these neoplasms refractory to cheJR-AB2-011 is a selective mTORC2 inhibitor with an IC50 value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association (Ki: 0.19 μM). JR-AB2-011...